Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.

Area of Science:

• Pharmaceutical Sciences
• Regulatory Affairs
• Public Health

Background:

• Compounded medications are essential for patients whose needs are not met by mass-manufactured drugs.
• Drug shortages and quality issues have complicated large-scale compounding pharmacy operations.
• State governments primarily regulate traditional pharmacy compounding.

Purpose of the Study:

• To examine the evolving landscape of prescription drug compounding.
• To understand the impact of recent legislation on compounding practices and regulation.
• To highlight the U.S. Food and Drug Administration's (FDA) role in overseeing drug compounding.

Main Methods:

• Analysis of the historical context of prescription compounding.
• Review of the Drug Quality and Security Act (DQSA) and its implications.
• Examination of the regulatory roles of states and the FDA in drug compounding.

Main Results:

• The DQSA establishes a clear distinction between traditional compounding and compounding manufacturing.
• The legislation standardizes rules for compounding manufacturers nationally.
• It preserves state authority in regulating traditional pharmacy compounding.
• The FDA's oversight of human drug compounding is clarified, with an emphasis on state coordination.

Conclusions:

• The DQSA aims to improve the safety and quality of compounded drugs.
• The act balances national uniformity for manufacturers with state-level regulation of traditional compounding.
• Collaboration between the FDA and states is crucial for ensuring compounded drug safety.